Channing J Paller

List of Publications by Year in Descending Order

65 papers	3,830 citations	21 h-index	61 g-index
69 ext. papers	4,924 ext. citations	6 avg, IF	5.12 L-index

#	Paper	IF	Citations
65	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.. *Prostate Cancer and Prostatic Diseases*, **2022**,	6.2	1
64	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.. *Value in Health*, **2022**, 25, 796-802	3.3	0
63	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).. *Journal of Clinical Oncology*, **2022**, JCO2102517	2.2	0
62	A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. *Kidney Cancer*, **2022**, 1-13	0.6	1
61	Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2022**, 42, 1-8	7.1	0
60	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.. *European Urology Open Science*, **2021**, 34, 70-78	0.9	0
59	Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. *JAMA Oncology*, **2021**, 7, 412-420	13.4	14
58	Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis. *Journal of the National Cancer Institute*, **2021**,	9.7	4
57	The Society for Integrative Oncology Practice Recommendations for online consultation and treatment during the COVID-19 pandemic. *Supportive Care in Cancer*, **2021**, 29, 6155-6165	3.9	5
56	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. *Journal of Clinical Oncology*, **2021**, 39, 1371-1382	2.2	22
55	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. *European Urology Oncology*, **2021**, 4, 447-455	6.7	20
54	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. *European Urology*, **2021**, 79, 692-699	10.2	17
53	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 387-395	4	11
52	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. *European Urology*, **2021**, 80, 632-640	10.2	14
51	Val16A SOD2 Polymorphism Promotes Epithelial-Mesenchymal Transition Antagonized by Muscadine Grape Skin Extract in Prostate Cancer Cells. *Antioxidants*, **2021**, 10,	7.1	1
50	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. *European Journal of Cancer*, **2021**, 144, 302-309	7.5	3
49	Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer-Reply. *JAMA Oncology*, **2021**, 7, 1069-1070	13.4	

48	Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. *Biomedicines*, **2021**, 9,	4.8	4
47	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. *Prostate*, **2021**, 81, 1382-1389	4.2	1
46	PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. *Cancers*, **2020**, 12,	6.6	35
45	A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). *BMC Cancer*, **2020**, 20, 492	4.8	6
44	Relationship of sex steroid hormones with bone mineral density of the lumbar spine in adult men. *Bone and Joint Research*, **2020**, 9, 139-145	4.2	1
43	Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations. *Scientific Reports*, **2020**, 10, 4106	4.9	10
42	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 650-659	13.4	297
41	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. *JCO Oncology Practice*, **2020**, 16, 811-819	2.3	16
40	Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. *Cancers*, **2020**, 12,	6.6	6
39	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 948-956	4	21
38	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. *Clinical Genitourinary Cancer*, **2019**, 17, 470-475.e1	3.3	9
37	Racial Inequality in Prostate Cancer Outcomes-Socioeconomics, Not Biology. *JAMA Oncology*, **2019**, 5, 983-984	13.4	12
36	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). *BMC Cancer*, **2019**, 19, 572	4.8	2
35	Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials. *Frontiers in Medicine*, **2019**, 6, 122	4.9	7
34	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. *Clinical Genitourinary Cancer*, **2019**, 17, 275-282.e1	3.3	22
33	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. *JCO Precision Oncology*, **2019**, 3,	3.6	15
32	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. *Prostate*, **2019**, 79, 1597-1603	4.2	14
31	Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. *World Journal of Nuclear Medicine*, **2019**, 18, 424-427	0.6	0

30	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. *Journal of Urology*, **2019**, 201, 735-741	2.5	16
29	TGF-receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. *Prostate*, **2019**, 79, 31-43	4.2	29
28	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. *Journal of the National Cancer Institute*, **2019**, 111, 118-128	9.7	33
27	Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest, and decreasing migration through heat shock protein 40. *Heliyon*, **2019**, 5, e01128	3.6	5
26	Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. *Antioxidants*, **2018**, 7,	7.1	46
25	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. *Lancet Oncology, The*, **2018**, 19, 76-86	21.7	100
24	Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. *Clinical Cancer Research*, **2018**, 24, 306-315	12.9	24
23	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. *JCO Precision Oncology*, **2018**, 2018,	3.6	10
22	Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report. *Clinical Genitourinary Cancer*, **2017**, 15, e839-e842	3.3	4
21	Risk factors for metastatic prostate cancer: A sentinel event case series. *Prostate*, **2017**, 77, 1366-1372	4.2	2
20	A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). *BMC Cancer*, **2017**, 17, 453	4.8	60
19	State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report. *Journal of the National Cancer Institute Monographs*, **2017**, 2017,	4.8	7
18	Detection fidelity of AR mutations in plasma derived cell-free DNA. *Oncotarget*, **2017**, 8, 15651-15662	3.3	19
17	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. *Prostate*, **2016**, 76, 1218-26	4.2	45
16	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. *Prostate*, **2016**, 76, 512-20	4.2	15
15	Challenges of conducting clinical trials of natural products to combat cancer. *Clinical Advances in Hematology and Oncology*, **2016**, 14, 447-55	0.6	18
14	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. *Clinical Genitourinary Cancer*, **2016**, 14, e515-e520	3.3	15
13	Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital. *Urology*, **2015**, 86, 539-43	1.6	21

12	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. *Prostate*, **2015**, 75, 1518-25	4.2	70
11	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. *JAMA Oncology*, **2015**, 1, 582-91	13.4	441
10	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *New England Journal of Medicine*, **2014**, 371, 1028-38	59.2	1753
9	Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. *Cancer Medicine*, **2014**, 3, 1322-35	4.8	22
8	Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. *Clinical Cancer Research*, **2014**, 20, 4210-7	12.9	41
7	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. *Clinical Advances in Hematology and Oncology*, **2013**, 11, 14-23	0.6	107
6	Association between sex steroid hormones and hematocrit in a nationally representative sample of men. *Journal of Andrology*, **2012**, 33, 1332-41		18
5	Management of bone metastases in refractory prostate cancer--role of denosumab. *Clinical Interventions in Aging*, **2012**, 7, 363-72	4	20
4	Finasteride and prostate cancer: a commentary. *Oncologist*, **2012**, 17, 888-90	5.7	1
3	Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. *Human Vaccines and Immunotherapeutics*, **2012**, 8, 509-19	4.4	15
2	Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. *Clinical Endocrinology*, **2009**, 70, 26-34	3.4	46
1	Sex-based differences in pain perception and treatment. *Pain Medicine*, **2009**, 10, 289-99	2.8	233